<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285544</url>
  </required_header>
  <id_info>
    <org_study_id>Lipinon Study</org_study_id>
    <secondary_id>H-0807-056-251</secondary_id>
    <nct_id>NCT01285544</nct_id>
  </id_info>
  <brief_title>The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia</brief_title>
  <official_title>Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong-A Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There will be no significant differences in the efficacy and tolerability between the test
      and reference formulations of atorvastatin 20 mg in these Korean adults with primary
      hypercholesterolemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percent change of LDL-C level</measure>
    <time_frame>After taken medication for 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percent change in total cholesterol, triglyceride, high density lipoprotein cholesterol (HDL-C) level, apolipoprotein B/A1 ratio, LDL/HDL ratio, small dense LDL fraction, high-sensitive C reactive protein (hs-CRP)</measure>
    <time_frame>After taken medication for 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Lipinon-test formulation of atrovastain - 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor- branded formuation of atorvastatin-20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipinon)</intervention_name>
    <description>treatment of dyslipidemia administration : PO, qod</description>
    <arm_group_label>Lipinon-test formulation of atrovastain - 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipitor)</intervention_name>
    <description>treatment of dyslipidemia administration : PO, qod</description>
    <arm_group_label>Lipitor- branded formuation of atorvastatin-20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  the patients aged 20 to 79 years with primary hypercholesterolemia that was not
             sufficiently responsive to therapeutic lifestyle changes and had LDL-C level over 100
             mg/dL in high risk group.

          -  Inclusion criteria was in accordance with drug treatment guidelines; coronary artery
             disease or equivalent group with LDL-C ≥100 mg/dl; patients with two or more risk
             factors and LDL-C≥130 mg/dl; patients with 0 or 1 risk factor and LDL-C &gt;160 mg/dl
             after therapeutic lifestyle changes

        Exclusion Criteria:

          -  therapy with any other investigational drug within 30 days of randomization,

          -  history of hypersensitivity to HMG-CoA reductase inhibitors,

          -  uncontrolled hypertension,

          -  poorly controlled diabetes (glycosylated hemoglobin [HbA1c] &gt;9%),

          -  unstable angina or presented with new-onset myocardial infarction (within 6 months),

          -  creatinine &gt;2.5 mg/dl,

          -  alanine aminotransferase (ALT) &gt;2 x upper limit of normal (ULN), aspartate
             aminotransferase(AST) &gt;2 x ULN, or creatine kinase (CK) &gt;2 x ULN,

          -  history of malignancy or psychosis;

          -  chronic liver disease,

          -  drug or alcohol abuse, pregnancy, breastfeeding, failure to practice adequate
             contraception, cyclical hormonal contraceptives or intermittent use of hormone
             replacement therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>December 15, 2013</last_update_submitted>
  <last_update_submitted_qc>December 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <keyword>statins</keyword>
  <keyword>cholesterol</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>Dyslipidemia in cardiovascular disease (KoLipinon)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

